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Abstract
Background: The Pr55
gag (Gag) polyprotein of HIV serves as a scaffold for virion assembly and is thus essential for progeny
virion budding and maturation. Gag localizes to the plasma membrane (PM) and membranes of late endosomes, allowing
for release of infectious virus directly from the cell membrane and/or upon exocytosis. The host factors involved in Gag
trafficking to these sites are largely unknown. Upon activation, CD4+ T cells, the primary target of HIV infection, express the
class II transcriptional activator (CIITA) and therefore the MHC class II isotype, HLA-DR. Similar to Gag, HLA-DR localizes to
the PM and at the membranes of endosomes and specialized vesicular MHC class II compartments (MIICs). In HIV producer
cells, transient HLA-DR expression induces intracellular Gag accumulation and impairs virus release.
Methodology/Principal Findings: Here we demonstrate that both stable and transient expression of CIITA in HIV producer
cells does not induce HLA-DR-associated intracellular retention of Gag, but does increase the infectivity of virions. However,
neither of these phenomena is due to recapitulation of the class II antigen presentation pathway or CIITA-mediated
transcriptional activation of virus genes. Interestingly, we demonstrate that CIITA, apart from its transcriptional effects, acts
cytoplasmically to enhance Pr160
gag-pol (Gag-Pol) levels and thereby the viral protease and Gag processing, accounting for
the increased infectivity of virions from CIITA-expressing cells.
Conclusions/Significance: This study demonstrates that CIITA enhances HIV Gag processing, and provides the first evidence
of a novel, post-transcriptional, cytoplasmic function for a well-known transactivator.
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Introduction
HIV polyprotein Gag serves as a scaffold to promote assembly
of progeny virions at cellular membranes [1] and recruits
components of the vesicular protein sorting pathway to facilitate
virus budding [2,3,4]. Concomitantly, the virally encoded protease
begins to cleave Gag, which is required for complete virion
maturation and infectivity [5,6,7]. Gag proteins can be detected at
both the PM and the membranes of endosomes among different
cell types, suggesting that budding is not limited to one cell-type
specific locale [8,9,10,11,12,13,14,15,16]. Further, host factors
which participate in targeting Gag trafficking to particular
membranes are largely unknown. As Gag and infectious virus
can originate from two cellular locations, two models for Gag
trafficking have emerged. The first model proposes that following
synthesis, Gag traffics to endosomal membranes, and upon
exocytosis is deposited on the PM, where it serves as the site for
productive virus assembly [14,17]. The second model proposes
that Gag is first trafficked to the PM, where virus assembly occurs,
and then excess Gag is internalized to intracellular compartments
[14,18,19,20], that serve as sites of productive virus assembly
[15,21].
MHC class II heterodimers follow a similar trafficking route,
appearing at both the PM and specialized multivesicular bodies
(MVBs) called MHC class II containing compartments (MIICs)
[22]. MHC class II is utilized by antigen presenting cells (APCs) to
present exogenous processed antigen to CD4+ T cells [22,23,24].
MHC Class II genes, including: HLA-DR, -DP and –DQ and the
accessory molecules, invariant chain (Ii) and HLA-DM, are
transcriptionally activated by the class II transactivator (CIITA),
the global regulator of coordinate class II MHC gene expression
[25,26]. As CIITA is induced in CD4+T cells upon activation,
these cells express MHC class II [27,28]. Upon synthesis, HLA-
DR heterodimers are assembled in the ER and the immature
complex (HLA-DR+ Ii) travels through the secretory pathway to
MIICs, where the specialized HLA-DM chaperone loads the
HLA-DR heterodimer with peptide [22,29,30]. Interestingly, both
immature and mature forms of HLA-DR can be found at the PM
and can be subsequently internalized to MIICs due to a di-leucine
motif in the cytoplasmic tail of Ii (immature HLA-DR) and a di-
leucine motif and/or ubiquitination of conserved lysine residues
within the HLA-DR b chain (mature HLA-DR), respectively
[22,29,31,32,33,34,35,36]. Therefore, a connection between HLA-
DR and Gag trafficking would not be surprising as both have an
alternative route to intracellular compartments by way of the PM.
Indeed, expression of HIV-1 Nef, Vpu and Gag have been shown
to alter HLA-DR trafficking [37,38,39,40]. In addition, HLA-DR
is preferentially acquired on the viral envelope of budding virions,
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apoptosis of T lymphocytes [41,42,43]. Therefore, HLA-DR locali-
zation at virus assembly sites is not unexpected.
Finzi et al. (2006) addressed the contribution of MHC class II-
induced MIIC formation to Pr55Gag trafficking by monitoring
virus budding in the presence of transiently expressed HLA-DR
heterodimers [8]. In HEK-293T cells expressing HLA-DR, there
was a marked redistribution of Gag to intracellular compartments,
and reduced virus release at the PM; mature virus budded into
HLA-DR containing multivesicular bodies and was retained [8].
We hypothesized that recapitulating endogenous expression of the
entire class II antigen presentation pathway in producer cells via
expression of CIITA would restore infectious virus release and
provide a more physiologically relevant model for HIV-1 assembly
studies. As expected, stable or transient expression of CIITA did
not induce intracellular retention of Gag. However, HLA-DR
induced Gag retention could not be alleviated by transient
co-expression with HLA-DM and/or Ii, or CIITA-mediated
upregulation of the recycling endosome GTPase, Rab4B [44].
Further, mutating ubiquitinatible lysine residues or complete
truncation of the cytoplasmic tails of the HLA-DR a and b chains
did not restore virus release. Rather, limiting the amount of HLA-
DR DNA transfected into cells restored virus release and alleviated
Gag retention. Curiously, CIITA expressing cells produced virus
that was significantly more infectious than CIITA deficient cells,
and this was independent of the class II antigen presentation
pathway. CIITA enhances infectivity of virions from producer
cells through a novel function, by improving maturation through
an increase in viral protease-dependent Gag processing. Using a
panel of CIITA mutants, we demonstrate that cytoplasmic CIITA
increases Gag-Pol polyprotein levels. Overall, our work reveals a
novel cytoplasmic, post-transcriptional function of CIITA, which
is expressed upon T cell activation and is constitutively expressed
in macrophages and dendritic cells, all known targets of HIV
infection.
Results
CIITA expression does not induced HLA-DR-mediated
Gag retention
Transient expression of the class II heterodimer, HLA-DR,
induces intracellular accumulation of Gag and a marked reduction
in extracellular virus release from producer cells [8]. This previous
study focused on HLA-DR in the absence of Ii and HLA-DM,
critical components of the antigen processing and presentation
pathway which influence MHC class II trafficking. To determine if
expression of the complete MHC class II pathway could overcome
Gag and virus retention we used CIITA to coordinately express
these genes. Cells were either transiently (pcCIITA) or stably
(A293T-CIITA) transfected with CIITA (Figure S1) and HIV-
1NL4-3 DNA, and Gag localization was monitored by immunoflu-
orescence and compared to cells transiently expressing the HLA-DR
a and b heterodimers (pcDRab1b5), or vector-only (pcDNA3.1). As
expected, a weak but uniform Gag signal was present in vector-only
transfected cells (Figure 1Aa) and transient HLA-DR expression
induced a marked redistribution of Gag as indicated by a dense,
punctuate Gag staining pattern (Figure 1Ad). Conversely, Gag
accumulation was not observed when CIITA was either transiently
or stably expressed (Figure 1Ab or c, respectively). Therefore,
transient expression of HLA-DR in producer cells does indeed lead
to Gag retention, which is not observed in the presence of CIITA.
However, recapitulation of the MHC class II pathway in trans
(pcDRab1b5+Ii+HLA-DMab), alsoresulted indenseaccumulation
of Gag signal (Figure 1Ae), suggesting that CIITA-mediated
coordinate activation of HLA-DR, -DM and Ii expression is
insufficient to overcome Gag retention. Flow cytometric analysis
confirmed these findings, as cells transfected with HLA-DR
heterodimers and/or co-transfected with some or all of the
components of the class II antigen presentation pathway stained
asGag
hi,indicatingGag accumulation(Figure 1BandC).However,
this population was absent in cells transiently or stably expressing
CIITA (Figure 1B and C). Therefore, absence of Gag accumulation
inCIITAexpressing cellsislikelynot duetoitstransactivationofthe
MHC class II antigen presentation pathway.
CIITA increases virion infectivity independently of
HLA-DR and the class II pathway
To assess whether CIITA-mediated alleviation of Gag retention
in class II expressing cells correlated with restored virus pro-
duction, virus particle and infectious virus release were measured
by p24 ELISA and GHOST cell infectivity assays, respectively.
Virus release, both infectious and particle titers) were reduced
when cells were transfected with either HLA-DR or other com-
ponents of the MHC class II antigen presentation pathway (Figure
S2), confirming a correlation between Gag retention and reduced
virus titers in the presence of HLA-DR, as previously demon-
strated [8]. These assays also demonstrate a dramatic increase in
infectious virus release from CIITA-expressing cells as compared
to cells expressing vector only (Figure 2A & S2), despite signifi-
cantly fewer virus particles being released from a CIITA-
expressing cell (as measured by pg/mL of p24 in the culture
supernatant, Figure 2B & S2). Therefore, while fewer virus
particles are released from a CIITA- expressing cell, those particles
are significantly more infectious (Figure 2C).
Previously, HLA-DR incorporation into the envelope of
budding virions was demonstrated to enhance virion infectivity
[45,46]. To determine if CIITA-enhancement of virion infectivity
was due to HLA-DR or other components of the class II antigen
presentation pathway, we measured virion infectivity from cells
expressing these proteins. However, virions from these cells were
just as infectious as virions released from vector only controls, yet
not as infectious as virions from cells either stably or transiently-
expressing CIITA (Figure 2D). Therefore, CIITA enhancement of
virion infectivity is independent of the MHC class II antigen
presentation pathway. Together, these data suggest CIITA has
two effects on the HIV replicative cycle in producer cells, both
of which are independent of the MHC II antigen processing
pathway; i) it does not induce HLA-DR, mediated intracellular
retention of Gag and ii) it increases the infectivity of HIV virions.
Rab4B does not alleviate HLA-DR mediated Gag
retention
CIITA has been shown to upregulate expression of Rab4B, a
small GTPase involved in endocytic recycling [44,47]. Therefore,
we hypothesized that CIITA via the action of Rab4B, could
increase Gag recycling back to the PM, thereby alleviating HLA-
DR-mediated Gag retention. Commercially available Rab4
antibodies cannot distinguish between Rab4A and 4B. However,
Krawczyk et al. (2007) demonstrated by chromatin immunopre-
cipitation that CIITA specifically associates with the Rab4B and
not the Rab4A promoter [44]. Immunoblotting demonstrated that
there is an increase in Rab4 in CIITA-expressing cells (Figure 3A),
therefore it is likely that this is in the form of Rab4B. However,
when Rab4B and HLA-DR were co-expressed in producer cells
with the HIV-1NL4-3 plasmid, it did not rescue intracellular
retention of Gag (Figure 3B). In fact, infectious virus release from
cells transiently co-expressing Rab4B and HLA-DR was further
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mediated retention of Gag (Figure 3C).
Up until this point, we had not co-expressed CIITA with HLA-
DR in producer cells to determine if CIITA could alleviate
retention of Gag and/or restore infectious virus release as would
be expected. Interestingly, when CIITA was transiently expressed
with the HLA-DR heterodimers in producer cells, Gag still
accumulated intracellularly and infectious virus production
remained reduced (Figure 3B and C, respectively), suggesting that
expression of CIITA is not sufficient to compensate for HLA-DR-
mediated Gag retention. However, when HLA-DR is endogenously
expressed under the control of CIITA, retention is alleviated.
Gag retention is an artifactual effect of HLA-DR
overexpression
Previously, Finzi et al. (2006) demonstrated that Gag retention in
HLA-DR+, multivesicular bodies could be alleviated when the
cytoplasmic tails of the HLA-DR a and b chains were removed
Figure 1. CIITA does not induce HLA-DR-mediated Gag retention. A293T cells were co-transfected with indicated plasmids and HIV-1NL4-3
and following intracellular staining of Gag (using an antibody which recognizes the CA p24 domain of Gag), immunofluorescence microscopy (A) and
flow cytometry (B) were performed. Total levels of Gag present in cells as well as cells which contain dense staining of Gag (Gaghi) are depicted (C).
Data are representative of three independent experiments.
doi:10.1371/journal.pone.0011304.g001
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b chain induces intracellular accumulation of class II heterodimers
in MHC class II compartments (MIICs) [35,36]. Thus, the
ubiquitination state of HLA-DR, might influence Gag retention.
To address this idea, Lys225Arg (pcDRabK225R) and Lys222/
225Arg (pcDRabK222/225R) point mutations were made in the
HLA-DR beta chain. Despite these mutations, HLA-DR expres-
sion on the surface of A293T cells was not significantly altered
(flow cytometric data not shown), nor was intracellular retention of
Gag alleviated or infectious virus release restored (Figure 4A
and B, respectively). Therefore, we attempted to alleviate Gag
retention and restore infectious virus release, as demonstrated by
Finzi et al. (2006) [8], by complete truncation of the cytoplasmic
tails of both HLA-DR a and b (pcDRaDcyto and pcDRbDcyto,
respectively). However, loss of either cytoplasmic tail (pcDRaDcy-
tob and pcDRabDcyto), or both cytoplasmic tails (pcDRaDcy-
tobDcyto), from the heterodimer did not alleviate Gag retention
and even further reduced infectious virus release from these cells
(Figure 4A and B, respectively). Our results may differ from Finzi’s
because of the differences in cell type, or HLA-DR gene alleles,
nevertheless they strongly suggest that transient HLA-DR
expression in producer cells induces Gag retention. Further, flow
cytometry to monitor surface HLA-DR expression demonstrates
that transient transfection of HLA-DR induces an approximate
half-log to log-fold increase in HLA-DR as compared to cells
stably or transiently expressing CIITA, respectively (Figure S1).
Therefore, it is possible that HLA-DR induced Gag retention is a
consequence of HLA-DR overexpression in this transient system
Figure 2. CIITA increases virion infectivity independently of HLA-DR and the class II pathway. Producer cells were transfected with
HIV-1NL4-3 and the indicated plasmids (A293T-CIITA is a stable clone) and at 48 h.p.t. infectious virus (A) and virus particle release (B) was determined
by a GHOST infectivity assay and p24 ELISA, respectively. The number of infectious virions per total number virions released from a live cell was also
determined (C). Similarly, the infectivity of virions from cells expressing HIV-1NL4-3 and the indicated constructs was determined (D). Standard
deviation of the mean for $5 independent experiments is presented. Statistical significance (p#0.05) was determined by a two-sample unequal
variance student’s T-test.
doi:10.1371/journal.pone.0011304.g002
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result in the same phenotype.
To test this possibility, virus producer cells were transfected with
increasing amounts of HLA-DR in the presence of HIV-1NL4-3
DNA, and infectious virus release was monitored. As HLA-DR
expression increased, the level of infectious virus release decreased
(Figure 4C). Further, while not statistically significant, there was a
positive correlation (r=0.9954) between Gag accumulation
(Gag
hi) and increasing HLA-DR expression (Figure 4D), suggest-
ing Gag retention is likely related to HLA-DR overexpression.
Similarly, when HLA-DM, which is structurally similar to HLA-
DR, was overexpressed in producer cells, Gag retention was
also induced (Figure 4D) and infectious virus release reduced (data
not shown). As endogenous expression of the class II antigen
presentation pathway by CIITA does not induce Gag retention
and limiting expression of HLA-DR or –DM likewise has a limited
effect on Gag retention in producer cells, these data collectively
suggest that overexpression of the class II pathway alters Gag
trafficking in producer cells leading to reduced infectious virus
release. However, these data do not provide an explanation for the
increased infectivity of virions released from CIITA-expressing
cells.
CIITA expression enhances virion maturation through
increased Gag processing
Viral protease cleavage of the Gag and Gag-Pol polyproteins is
required for virion maturation and infectivity [5,6]. The mature
complement of HIV-1 structural proteins includes matrix (MA
[p17]), capsid (CA [p24]), nucleocapsid (NC[p7]) and p6, as well
as spacer peptides, SP1 [p2] and SP2 [p1] within Gag (Figure 5A).
The enzymatic proteins, integrase (IN[p32]), reverse transcriptase
(RT [p66/51]) and protease [p10], as well as the transframe
octapeptide (TFP) and p6* are generated from the Gag-Pol
polyprotein (Figure 5A) [13,48,49,50,51]. As there is an increase in
virion infectivity from CIITA-expressing cells, we hypothesized
that the processing of Gag polyproteins may be enhanced in these
cells. As suspected, analysis of cell lysates from equal numbers of
HIV-1 transfected A293T-CIITA and A293T cells demonstrated
a higher ratio of mature CAp24 to Pr55Gag in CIITA-expressing
cells (Figure 5 B&C), demonstrating that Gag processing in the
presence of CIITA is enhanced. Additionally, increased levels of
processing intermediates are present in A293T cell lysates.
Specifically, the p41 (MA-CA-SP1) and p25 (CA+p2) products
were increased (Figure 5 B&C) in these cells, indicating that Gag
processing in the presence of CIITA is more efficient. Gag
processing is also enhanced in cell-free virions from cells either
transiently or stably expressing CIITA, as demonstrated by the
increased levels of CAp24, and the loss of the p41 and p25
intermediate products relative to Pr55Gag (Figure 5D&E).
Collectively, these results suggest that CIITA increases Gag
polyprotein processing, leading to enhanced production of
infectious virions.
HLA-DR does not increase Gag processing
HLA-DR is incorporated into the HIV virion envelope [52] and
is transcriptionally activated by CIITA, therefore its contribution
to Gag processing was assessed. Virions from HLA-DR-expressing
cells exhibited less Gag processing than virions from CIITA-
expressing cells (Figure 5F, bottom panel). When virions from both
cell lines were affinity-purified on HLA-DR binding columns, Gag
processing was reduced in those produced in the HLA-DR-
expressing cells as compared to virions from cells which express
CIITA (Figure 5F, upper panel and 5G), suggesting that HLA-DR
alone does not contribute to increased Gag processing. Similar to
our previous results, there are fewer processing intermediates
present in virions from CIITA-expressing cells, suggesting that
CIITA expression enhances virion infectivity by increasing
maturation through more complete Gag processing.
CIITA enhancement of Gag processing is through the
viral protease activity
Cleavage of the Gag and Gag-Pol polyprotein is mediated
specifically by the virally-encoded protease [53,54,55]. We
considered that CIITA might increase viral protease processing
of Gag; thus, we examined Gag processing and infectious virus
release from CIITA-expressing HIV producer cells in the presence
of a protease inhibitor. If CIITA is increasing protease processing,
such an enhancement should be overcome by lower doses of the
Figure 3. Rab4B does not alleviate HLA-DR mediated Gag retention. The level of Rab4 expressed in CIITA-expressing A293T cells was
determined by immunoblotting, where b-actin served as a loading control (A). Cells were co-transfected with the indicated constructs and HIV-1NL4-3
and Gag retention was monitored by intracellular staining and flow cytometry (B) and infectious virus release was measured via GHOST infectivity
assays (C). Data are representative of three independent experiments and error bars indicate standard error.
doi:10.1371/journal.pone.0011304.g003
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trations of 0.6 and 1.25 nM of Lopinavir infectious virus release
from CIITA-expressing cells was reduced to that of A293T cells
treated with vehicle only (Figure 6A). To determine if the reduced
Gag processing correlated with decreased infectious virus release,
we monitored Gag cleavage by western blotting and as expected,
between 0.6 and 1.25 nM of Liponavir, Gag processing in virions
from CIITA-expressing cells was returned to that of vehicle
treated, vector-only control cells (Figure S3). These results directly
demonstrate that CIITA-mediated enhancement of Gag process-
ing and infectious virus release is through the HIV protease.
CIITA acts cytoplasmically to improve and enhance Gag
processing
The only known function of CIITA is as a transcriptional co-
activator; therefore, we thought it likely that it drives the
expression of a gene which enhances viral protease-mediated
Gag processing. Therefore, we reasoned that expression of CIITA
mutants which fail to localize to the nucleus should not mediate
increased Gag processing or enhanced infectious virus release. To
test this idea, a panel of CIITA mutants (GTP2, a magnesium ion
coordination site mutant and GTP3, a guanine ring-binding domain
mutant and L1035P, a point mutant in the C-terminal leucine rich
repeat domain, which are all defective for nuclear localization and
fail to activate HLA-DRA transcription [56,57,58]), were individ-
ually co-expressed with HIV-1NL4-3 DNA, and infectious virus
release and Gag processing were monitored. Interestingly, producer
cellsexpressing thesemutants alsoproducedmore infectiousvirus as
compared to vector-only control (Figure 7A) and had increased Gag
processing in both cell-bound virions and cell-freevirions (Figure 7B
and Figure S4, respectively). Loss of CIITA nuclear localization
(and therefore coactivation potential), did not hinder increased
Gag processing and infectious virus release, strongly suggesting
that CIITA acts cytoplasmically to increase HIV virus maturation
Figure 4. MHC class II- induced Gag retention is a consequence of HLA-DR overexpression in producer cells. Mutations were made in
the HLA-DR cytoplasmic tails as indicated and transfected into producer cells at a 1:1 ratio with HIV-1NL4-3 and Gag retention by flow cytometry (A)
and infectious virus release (B) was monitored. Decreasing amounts of HLA-DR a and b heterodimer constructs were transfected into producer cells
with HIV-1NL4-3 and infectious virus release (C) and Gag retention (D) were monitored. Data are representative of three independent experiments and
error bars indicate standard error.
doi:10.1371/journal.pone.0011304.g004
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PLoS ONE | www.plosone.org 6 June 2010 | Volume 5 | Issue 6 | e11304Figure 5. CIITA enhances virion maturation through increased Gag processing. Diagram of Pr55Gag and Pr160Gag-Pol and their respective
cleavage products (A). Protein lysates from cell equivalents of HIV-1NL4-3 transfected vector-only (A293T) or CIITA expressing (A293T-CIITA) cells (B)
were western blotted with an antibody which recognizes CAp24 of Gag. Similarly, cell-free virions from vector-only (A293T), transient-CIITA
expressing (pcCIITA) or stably-expressing CIITA (A293T-CIITA) (D), or virions affinity purified with biotinylated-anti-HLA-DR antibody (L243) on
streptavidin-coated magnetic beads (F, top panel, where bottom panel is input control virus), were western blotted for Gag processing.
Densitometric analysis of western blots was performed and quantitative analysis of Gag cleavage products is presented as percentage of total
reactive bands (C, E and G). Data are representative of three independent experiments.
doi:10.1371/journal.pone.0011304.g005
CIITA Enhances HIV Maturation
PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e11304Figure 6. CIITA enhancement of Gag processing and viral infectivity is through the viral protease. Following co-transfection with vector-
only (pcDNA3.1) or pcCIITA and HIV-1NL4-3, producer cells and were treated with indicated concentrations of Lopinavir and 17 h later infectious virus
titers were determined by GHOST assay (A) and Gag processing was measured via western blotting with antibody against CAp24 followed by
densitometric analysis of Gag cleavage products (B). Data are representative of three independent experiments.
doi:10.1371/journal.pone.0011304.g006
Figure 7. CIITA cytoplasmically increases Pr160Gag-Pol levels. Producer cells were transfected with the indicated CIITA constructs and
HIV-1NL4-3; 48 h later infectious virus titers were determined by GHOST assay (A, n.2, error bars rep. standard deviation of the mean). Gag processing
was measured via western blotting with antibody against CAp24 and densitometric analysis of Gag cleavage products (B). Producer cells were
transfected with indicated constructs and then 16 hours later with HIV-1NL4-3 before treatment with 80 nM Lopinavir at 4.5 hours post-transfection.
17 hours later, cell lysates were blotted with the indicated antibodies (C) and western blotting with antibody against CAp24 followed by
densitometric analysis allowed for the determination of the percentage of Gag-Pol and Gag, following normalization to b-actin (D). Unless indicated,
data are representative of three independent experiments.
doi:10.1371/journal.pone.0011304.g007
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CIITA transactivation potential as a mechanism of enhanced virus
release utilizing a different model system. NIH 3T3 BALB/c cells
(expressing human p32 to allow for virus like particle production
[59]) expressing CIITA and transfected with an LTR-deficient HIV
genome construct (pcHIV PAL),under control of a CMV promoter
had a dramatic increase in virus-like particle production as com-
pared to NIH 3T3 cells in the absence of CIITA (Figure S5). This
result provides further evidence that CIITA enhancement of virus
production is independent of its transactivation potential on the
HIV LTR.
CIITA increases the viral protease through increased
Gag-Pol levels
To determine the mechanism by which CIITA mediates
protease activity in these cells, we analyzed the expression of the
Gag and Gag-Pol in CIITA-expressing cells. Expression of the
HIV protease is extremely toxic to cells, and is thus very tightly
regulated during virus replication [60,61,62]. The viral protease
arises from the alternative Gag translation product (Figure 5A),
Gag-Pol which, accounts for only 2–10% of Gag polyproteins and
results from ribosomal frameshifting at a conserved heptamer
‘‘slippery sequence’’ and a secondary stem-loop structure on gag-pol
transcripts [51,63]. Therefore, increased viral protease-mediated
processing of the Gag polyproteins from CIITA-expressing cells
may be due to an increase in overall viral protease levels, due to
increased Gag-Pol synthesis. To establish the ability of CIITA to
mediate the enhanced production of HIV protease, cells were
transiently co-transfected with either CIITA or pcDNA and HIV-
1NL4-3 DNA, and were treated with 80 nM of Lopinavir to inhibit
the majority of Gag polyprotein processing. Gag-Pol levels relative
to Gag were then determined by western blotting. While 1–2% of
all Gag polyprotein in cell lysates of vector-only cells was in the
form of Gag-Pol, expression of CIITA increased this level to
almost 5% (Figure 7C and D), indicating that CIITA increases
Gag-Pol levels in virus producer cells. We also measured the
potential of the cytoplasmic CIITA mutants to increase Gag-Pol
levels relative to Gag and, interestingly, Gag-Pol made up
approximately 13, 20 and 15% of all Gag polyproteins in
GTP2, GTP3 and L1035P –expressing cells, respectively. This
result further demonstrates a novel transcription-independent role
for cytoplasmic CIITA during HIV infection, where CIITA
enhances Gag-Pol protease expression, which subsequently
enhances virus maturation and infectivity.
Discussion
Finzi et al. (2006) demonstrated that transient overexpression of
HLA-DR heterodimers in HEK-293 cells lead to redistribution of
Gag and intracellular accumulation of infectious virus in
multivesicular bodies (MVBs) [16]. We speculated that complete
expression of the antigen presentation pathway, through expres-
sion of CIITA, would alleviate this phenotype in virus producer
cells. Interestingly, we noticed two phenomena: i) CIITA did not
induce intracellular retention of Gag or impair virus release in
producer cells despite expression of HLA-DR and ii) the virus
released from cells expressing CIITA was significantly more
infectious. Upon investigation of CIITA-mediated alleviation of
HLA-DR-induced Gag retention, we found that this effect was not
due to the lack of Ii or HLA-DM (key components of antigen
presentation), as had been expected, nor was it a consequence of
Rab4B expression in these cells. Further, when lysine residues in
the HLA-DR chain were mutated or both of the HLA-DR chain
cytoplasmic tails were truncated, Gag was still retained and virus
release inhibited. In addition, when CIITA was expressed in
conjunction with HLA-DR this effect could not be alleviated,
suggesting that Gag retention is a consequence of HLA-DR
overexpression. Indeed, retention of Gag is directly correlated to
levels of HLA-DR expression. Further, we did not observe Gag
retention when class II antigen presentation pathway genes were
expressed at endogenous levels via CIITA expression. Overex-
pression of HLA-DM, which is structurally similar to HLA-DR
also induced Gag retention, suggesting that retention of Gag is a
likely consequence of altered trafficking of overexpressed class II
antigen presentation pathway components rather than a physio-
logically relevant phenomenon.
Despite observing similar HLA-DR and Gag retention/reduced
virus release effects as Finzi et al.(2006), our results differed in that
we did not observe the requirement for intact HLA-DR a and
b-chain cytoplasmic tails for the induction of Gag retention. In our
hands, when the ubiquitinatible lysine residues in the HLA-DR
b-chain were mutated or the cytoplasmic tails of the HLA-DR
dimer were completely removed, there was no alleviation of Gag
retention or virus release. Beyond the obvious differences between
the previous work [8] and our own (i.e. provirus construct and cell
type), our mutant data may differ from theirs because arginine
residues were substituted for lysine 215 and tyrosine 220 residues
in the HLA-DR a and b chain, respectively, in order to ensure
stabilization of the truncated HLA-DR molecule at cellular
membranes. These differences in mutant constructs may poten-
tially explain discrepancies in our results.
We also observed that expression of HLA-DM was sufficient to
induce Gag retention and impede virus release from cells.
However, Finzi et al.(2006) did not observe retention in the
presence of HLA-DM or HLA-DO [8]. This difference may be
explained by their use of a bicistronic construct for expression of
the HLA-DM heterodimer; however, this strategy was also used to
express HLA-DR, which still induced retention [8]. Irrespective of
these differences, Gag retention and loss of virus release correlates
with increasing HLA-DR expression. These results do not exclude
the possibility that HLA-DR and Gag trafficking may be linked.
Indeed, we have demonstrated that Gag co-immunoprecipitates
with HLA-DR from CIITA expressing cells and this interaction is
independent of the cytoplasmic tails of HLA-DR (data not shown).
Further, other HIV proteins may be linked to class II trafficking.
Stumptner-Cuvelette et al.(2003) and Chaudhry et al.(2009), have
independently demonstrated that HIV Nef induces internalization
of surface class II in epithelial and monocytic cell lines, respectively
[37,64]. However, we did not observe downregulation of HLA-
DR from the cell surface, following transfection of the HIV
genome into CIITA-expressing epithelial cells (data not shown) or
HIV infection of CIITA-expressing CD4+ T cells (unpublished
data). Further, Gluschankof and Suzan demonstrated that ex-
pression of Gag-Pol restored HLA-DR presence at the cell surface
in the H78-C10.0 line, a T cell clone deficient for surface HLA-
DR expression [40]. Collectively, our work and that of others
suggests a link between HLA-DR and Gag trafficking, where
localization may be cell-type dependent.
One of the more interesting findings of this study is that while
overall viral titers from CIITA-expressing cells decrease the
infectivity of these particles is significantly enhanced. Increased
infectivity was due to improved virion maturation in a viral
protease-dependent manner. Not only was processing to capsid
p24 more complete in CIITA expressing cells, but vector-only
control cells and those only expressing HLA-DR contained
increased levels of processing intermediates. The presence of
higher levels of processing intermediates in virus produced in these
cells may help explain the reduced infectivity, as studies in both
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products act transdominantly to reduce virion infectivity through
reduced reverse transcription of viral RNA, despite the presence of
functional Reverse Transcription polymerase [7].
Next we demonstrated that CIITA increased Gag processing
through the viral protease and evaluated whether this enhancement
was a consequence of CIITA-mediated transcriptional activation.
The CIITA L1035P mutant, which fails to translocate to the nucleus
[58], demonstrated increased Gag processing and virus release
compared to vector-only control, suggesting a cytoplasmic role for
CIITA in the later stages of the HIV infection cycle. This does not
preclude the possibility that an undetectable level of CIITA L1035P
might translocate to the nucleus. However, no L1035P was detected
in the nucleus after a 24 hour treatment with the nuclear export
inhibitor, leptomycin B [58]. Further, the predominantly cytoplasmic
GTP-binding CIITA mutants, GTP2 and GTP3, had a similar
increase in infectious virus release versus vector-only expressing cells.
Previously, it was demonstrated that increased Gag-Pol levels
severely impair virion infectivity through disruption of RNA
genome dimerization [62]. Further, HIV protease is known to be
toxic to cells as it leads to the production of the novel Procaspase 8
cleavage product, Casp8p41, which induces apoptosis through loss
of mitochondrial membrane potential [66]. Therefore, we would
expect that virions from CIITA-expressing cells would be reduced
in titer and infectivity, as there is increased Gag-Pol and protease.
However, while overall viral particle numbers (as measured by p24
ELISA) from CIITA expressing cells were decreased, the infectivity
of these virions was significantly increased when calculated by
infectious units per pg p24. Interestingly, at 0.6 nM Lopinavir, the
infectivity of virions from CIITA-expressing cells increased over
vehicle-treated controls, despite reduced Gag processing. Further,
the mutants of CIITA,which produced the highestlevel of Gag-Pol,
did not demonstrate a linear increase in Gag processing or virion
infectivity, which may be explained by previous work demonstrate-
ing that increased Gag-Pol levels impairs viral infectivity [61,62].
Therefore it is likely that CIITA is capable of increasing Gag-Pol
levels to a point which can impede virus maturation, albeit not
enough to reduce it to levels observed from vector-only expressing
cells. Therefore, overall infectivity of virions is increased from cells
expressing CIITA despite an altered Gag to Gag-Pol ratio. Future
studies should focus on how CIITA can increase this ratio without
severely impairing virus release as well the novel mechanism by
which CIITA increases Gag-Pol levels. Preliminary studies in this
laboratorysuggestthatCIITAenhancementGag-Polmaybedueto
increased ribosomal frameshifting (data not shown).
Finally, it is tempting to speculate that CIITA, which is expressed
uponCD4+ Tcellactivationandincreasesviralproteaselevels,may
also contribute to Casp8p41-mediated apoptosis, which may link
CIITA to the decimation of T cells in the GALT during primary
viremia [67]. Thymic epithelial cells [68], cervical epithelial cells
[69], human colonic epithelial cells [70] and oral keratinocytes
(normal human oral epithelial cells) [71] have all demonstrated in
vitro the capability of being productively infected with HIV.
Infection of epithelial cells provides potential in vivo significance to
this study, especially considering that thymic epithelial cells
constitutively express MHC class II (and thus CIITA) [28]. In
addition, most other cells can be stimulated to express CIITA in the
presence of IFN-c (i.e. a pro-inflammatory environment), which is
induced during HIV infection of the GALT [72]. Overall, this study
demonstrates that the function of CIITA may be more broad than
previously thought. Given this previously undescribed role in
enhancement of virion maturation, the precise consequences of
CIITA expression during the HIV replicative cycle may provide
rationale for the development of novel antiviral therapeutics.
Materials and Methods
Cell Culture
A293T cells [73] were maintained as previously described [74]
and CIITA-stable A293T cell lines were generated by co-
transfecting PVU I linearized pDNA3.FLAG.CIITA8 [75] and
pCMV4His, a mammalian selection vector which encodes the
histidinol dehydrogenase gene under control of the CMV pro-
moter into the cells. Stable clones were selected in DMEM
medium containing 5 mM L-histidinol (Sigma-Aldrich., St. Louis,
MO) and cloned by limiting dilution assay. GHOST cell medium
was supplemented with 0.2 mg/ml G418, 0.1 mg/ml hygromycin
B and 1 mg/ml puromycin (Sigma) as previously described [76].
Cloning and transfections
Using cDNA reverse transcribed from A293T-CIITA RNA, we
amplified HLA-DRa, HLA-DRb1 and HLA-DRb5 sequences
(GenBankaccessionnos.NM019111,NM002121, andNM002125,
respectively), using primers containing forward restriction site XbaI
and the reverse restriction site HindIII (Table S1). The haplotyping
of HLA-DR isotypes expressed by A293T cells was determined by
the Transplantation Immunology Lab, Albany Medical College.
Primers were designed to include an intact Kozak sequence
upstream of the translation start site. HLA-DRa and b5 plasmids
werethen used forsite-directedmutagenesis usingprimers indicated
(Table S1). Transient transfections of all plasmids, including:
pDNA3.FLAG.CIITA8 [75], CIITA-GTP2 and -GTP3 [56] and
CIITA -L1035P [58], p33-143 (codingfor the p33and p35isoforms
of invariant chain–a kind gift provided by Dr. Eric O. Long,
NIAID), HLA-DMa and b (pMCFR-PAC and pDMb/MCFR-
kindly provided by Dr. Lisa K. Denzin, Sloan-Kettering Cancer
Center), eGFP-Rab4B (kindly provided by Dr. Marci Scidmore,
Cornell University), and HIV Gag-iGFP [77] (kindly provided by
Dr. Benjamin Chen, Mount Siani School of Medicine) were
performed using a 3:1 ratio Fugene HD Transfection Reagent to
DNA in serum-free media as suggested by the manufacturer
(Roche, Indianapolis,IN).Virusplasmid DNAprovidedhalf oftotal
DNA used in transfection reactions.
NIH 3T3 Balb/c cells are transfected with 1.5 mg CIITA and
4.5 mL FuGene HD (7:2 ratio of FuGene to DNA for optimal cells
growth) and selected for with L-histidionol for two weeks and
analyzed for MHC II expressing using fluorescence-activated cell
sorter (FACS) with PE-conjugated mouse IgG2a (Cedar Lane)
against I-A
d and clones were selected by limiting dilution. These
cells were co-transfected with p32cDNA and pcHIV PAL (which
contains all HIV genes except the LTR sequences) at a 2:1 ratio.
The p32cDNA was donated by the Peterlin laboratory [59]. Both
MHC II expressing VLPs and MHC II-negative VLPs were
produced and concentrated 10-fold in a 100 K molecular weight
cut-off filter tube (Millipore) for 15 minutes at 4000 rpm prior to
titering via HIV-1 p24 CA Antigen Capture Assay Kit were
performed following the manufacturer’s instructions (NIH AIDS
Research and Reference Reagent Program).
RNA Extraction
Cytoplasmic RNA from 48 hr cultures of each cell type was
collected using the RNeasy Mini Kit according to manufacturer’s
instructions (Qiagen, Inc., Valencia, CA).
RT-PCR
1ug of DNA-free RNA was run out on a non-denaturing gel to
ensure equal concentrations of each sample followed by reverse
transcription of 1 mgo fe a c hR N As a m p l eu s i n gt h ei S c r i p tc D N A
synthesis kit, following manufacturer’s instructions (BioRad, Hercules,
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and Ii from each cell type to confirm expression. Forward and
reverse primers sequences used in RT-PCR experiments indicated
in Table S1.
Flow Cytometry
Cells were analyzed for HLA-DR expression as previously
described [56]. Briefly, cells were incubated with murine clone
L243 [78] hybridoma (ATCC, Manassas,VA) supernatant diluted
1:10 in PBS/2% FBS for 30 minutes on ice, washed, and then
incubated with goat- anti-mouse Alexa-Fluor 488- or Alexa-Fluor
647-conjugated secondary antibody (Molecular Probes/Invitro-
gen) diluted 1:100 in PBS/2% FBS for 20 minutes on ice in the
dark. Alternatively, the cells were incubated with L243 monoclo-
nal antibody conjugated to AlexaFluor 488 or 647 (BioLegend)
diluted 1:50 in PBS/2% FBS for 40 minutes on ice in the dark.
Cells were then analyzed with the FACSCanto (BD Biosciences,
San Jose, CA) and further analyzed with Flo-Jo 7.2.2 software
(Tree Star, Inc, Ashland, OR). For Gag retention experiments, live
cells were gated, followed by gating of DR+ cells and then the
percentage of Gag and Gag
hi cells were gated. Microscopy on the
same samples was performed using Leica L2 microscope (Leica
Microsystems Wetler GmbH, Wetzler, Germany).
Western blotting
(1:000) of mouse anti-human Rab4 (BD, Franklin Lakes, NJ),
rabbit anti-human b-actin (Cell Signaling Tech., Danvers, MA),
(1:200) HIV-1 p24 hybridoma supernatant (183-H12-5C)[79],
(1:10,000, NIH AIDS Research and Reference Reagent Program,
Germantown, MD) and (1:1000) mouse anti-FLAG M2 (Sigma).
Secondary antibodies used: HRP conjugated, Goat anti-Mouse
IgG and Goat anti-Rabbit IgG (Zymed grade) or (Invitrogen,
Carlsbad, CA). Densitometric analysis was performed as previ-
ously described [80] and the percentage of total HIV-1 a CA p24
(183-H12-5C) [79] reactive bands was used as a measure of Gag
processing [81].
Intracellular Gag staining
10
6 cells were permeabilized with IntraPrep Permeabilization
Reagent (Beckman-Coulter, Fullerton, CA), following manufac-
turer’s instructions. Gag was stained with FITC-conjugated
FH190-1-1 (Beckman-Coulter) for approximately 15 m prior to
analysis and data interpretation as performed above, with the
exception of the percentage of Gag+ cells was determined after
gating on HLA-DR+ cells.
Virus purification and titering
Virions were purified using the mMACS Streptavidin Kit
(Miltenyi Biotec Inc., Auburn, CA.), according to the manufac-
turer’s instructions using biotinylated-L243 (Biolegend). GHOST
assay [82] to determine infectious virus production and p24
ELISAs to determine virus particle release using the HIV-1 p24
CA Antigen Capture Assay Kit were performed following the
manufacturer’s instructions (NIH AIDS Research and Reference
Reagent Program).
Protease inhibition
Cells were transfected with either pcCIITA or empty pcDNA
vector 4.5 hours prior to Lopinavir (NIH AIDS Research and
Reference Reagent Program) or DMSO (vehicle-only) treatment
at indicated concentrations. Virus and cell supernatants were
collected approximately 17 hours post-treatment. For determina-
tion of p160Gag-Pol to p55Gag ratios, producer cells were
transfected with CIITA constructs (pcCITIA, GTP2, GTP3,
L1035P) or vector only control (pcDNA) and then transfected with
pNL4-3 16 hours later, prior to being treated with 80 nM
Lopinavir. Cell lysates were used to monitor the levels of Pr55Gag
to Pr160Pol via western blotting with HIV-1 a CA p24 (183-H12-
5C) after 17 hours.
Supporting Information
Table S1 Primers used in this study.
Found at: doi:10.1371/journal.pone.0011304.s001 (0.06 MB
DOC)
Figure S1 Gene expression analysis via semi-quantitative PCR
was performed on A293T cells transfected with the indicated
constructs (A), where the Hut78 T cell line served as a positive
control. Expression of HLA-DR on the surface of cells transfected
with the indicated plasmids was assessed by flow cytometry (B).
Found at: doi:10.1371/journal.pone.0011304.s002 (0.71 MB
DOC)
Figure S2 Virus titers were determined at 48 h.p.t. following
transfection with indicated plasmids and HIVNL4-3, as determined
by GHOST infectivity assays and p24 ELISA. Standard deviation
of the mean for 3 independent experiments is presented.
Found at: doi:10.1371/journal.pone.0011304.s003 (0.07 MB
DOC)
Figure S3 Representative blot of Gag processing in virions from
cells treated with indicated concentrations of Lopinavir, where
Vehicle = vehicle only (DMSO).
Found at: doi:10.1371/journal.pone.0011304.s004 (0.41 MB
DOC)
Figure S4 Gag processing of virions from cells transfected with
indicated constructs and HIVNL4-3 was measured via western
blotting with antibody against CAp24 followed by densitometric
analysis of Gag cleavage products.
Found at: doi:10.1371/journal.pone.0011304.s005 (0.07 MB
DOC)
Figure S5 p32cDNA and pcHIV PAL were cotransfected into
the indicated NIH 3T3 Balb/c cells. At 3 d.p.t. virus containing
supernatants were used for titering via p24 ELISA assay. Data is
representative of three independent experiments, where error bars
indicate standard error.
Found at: doi:10.1371/journal.pone.0011304.s006 (0.03 MB
DOC)
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